- Home
- UAA vs NAMS Comparison
UAA vs NAMS Comparison
Compare UAA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAA
- NAMS
- Stock Information
- Founded
- UAA 1996
- NAMS 2019
- Country
- UAA United States
- NAMS Netherlands
- Employees
- UAA N/A
- NAMS N/A
- Industry
- UAA Apparel
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- UAA Consumer Discretionary
- NAMS Health Care
- Exchange
- UAA Nasdaq
- NAMS Nasdaq
- Market Cap
- UAA 2.9B
- NAMS 2.5B
- IPO Year
- UAA N/A
- NAMS N/A
- Fundamental
- Price
- UAA $6.58
- NAMS $21.28
- Analyst Decision
- UAA Hold
- NAMS Strong Buy
- Analyst Count
- UAA 18
- NAMS 9
- Target Price
- UAA $7.47
- NAMS $41.11
- AVG Volume (30 Days)
- UAA 9.8M
- NAMS 804.3K
- Earning Date
- UAA 08-08-2025
- NAMS 08-11-2025
- Dividend Yield
- UAA N/A
- NAMS N/A
- EPS Growth
- UAA N/A
- NAMS N/A
- EPS
- UAA N/A
- NAMS N/A
- Revenue
- UAA $5,164,310,000.00
- NAMS $47,140,000.00
- Revenue This Year
- UAA N/A
- NAMS N/A
- Revenue Next Year
- UAA $2.91
- NAMS $73.09
- P/E Ratio
- UAA N/A
- NAMS N/A
- Revenue Growth
- UAA N/A
- NAMS 586.97
- 52 Week Low
- UAA $4.78
- NAMS $14.06
- 52 Week High
- UAA $11.89
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- UAA 41.84
- NAMS 48.31
- Support Level
- UAA $7.04
- NAMS $21.55
- Resistance Level
- UAA $7.47
- NAMS $24.18
- Average True Range (ATR)
- UAA 0.26
- NAMS 1.22
- MACD
- UAA -0.07
- NAMS -0.20
- Stochastic Oscillator
- UAA 12.33
- NAMS 17.50
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.